Theriva Biologics Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
22
- Stock Symbol
-
TOVX
- Investments
-
3
- Share Price
-
$1.42
- (As of Friday Closing)
Theriva Biologics General Information
Description
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Contact Information
Website
www.therivabio.comCorporate Office
- 9605 Medical Center Drive
- Suite 270
- Rockville, MD 20850
- United States
Corporate Office
- 9605 Medical Center Drive
- Suite 270
- Rockville, MD 20850
- United States
Theriva Biologics Stock Performance
As of 25-Apr-2025, Theriva Biologics’s stock price is $1.42. Its current market cap is $3.93M with 2.78M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.42 | $1.41 | $0.96 - $12.28 | $3.93M | 2.78M | 59.7K | -$19.03 |
Theriva Biologics Financials Summary
As of 31-Dec-2024, Theriva Biologics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (9,801) | (9,801) | (18,874) | (38,895) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (26,213) | (26,213) | (21,293) | (21,537) |
| Net Income | (25,653) | (25,653) | (18,349) | (19,685) |
| Total Assets | 35,352 | 35,352 | 55,219 | 71,861 |
| Total Debt | 1,565 | 1,565 | 2,154 | 1,681 |
Theriva Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Theriva Biologics Comparisons
Industry
Financing
Details
Theriva Biologics Competitors (46)
One of Theriva Biologics’s 46 competitors is Synlogic, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Synlogic | Formerly VC-backed | Cambridge, MA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| 4D pharma | Corporation | Leeds, United Kingdom | ||||
| XBiotech | Corporation | Austin, TX |
Theriva Biologics Patents
Theriva Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023324028-A1 | Treatment or prevention of gastrointestinal immunotherapy side effects | Pending | 09-Aug-2022 | ||
| AU-2023276693-A1 | Ulcerative colitis treatments in selected patients | Pending | 24-May-2022 | ||
| EP-4531861-A1 | Ulcerative colitis treatments in selected patients | Pending | 24-May-2022 | ||
| CA-3219706-A1 | Alkaline phosphatase-based treatments of celiac disease | Pending | 24-May-2021 | ||
| EP-4347017-A1 | Alkaline phosphatase-based treatments of celiac disease | Pending | 24-May-2021 | A61K38/465 |
Theriva Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Theriva Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Theriva Biologics Investments & Acquisitions (3)
Theriva Biologics’s most recent deal was a Merger/Acquisition with VCN Biosciences for . The deal was made on 10-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| VCN Biosciences | 10-Mar-2022 | Merger/Acquisition | Drug Discovery | ||
| Prev ABR (Clostridium Difficile Infectious Disease Program) | 28-Nov-2012 | Corporate Asset Purchase | Buildings and Property | ||
| Adeona Pharmaceuticals | 16-Feb-2012 | Merger/Acquisition | Pharmaceuticals |
Theriva Biologics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Theriva Biologics FAQs
-
When was Theriva Biologics founded?
Theriva Biologics was founded in 2001.
-
Where is Theriva Biologics headquartered?
Theriva Biologics is headquartered in Rockville, MD.
-
What is the size of Theriva Biologics?
Theriva Biologics has 22 total employees.
-
What industry is Theriva Biologics in?
Theriva Biologics’s primary industry is Drug Discovery.
-
Is Theriva Biologics a private or public company?
Theriva Biologics is a Public company.
-
What is Theriva Biologics’s stock symbol?
The ticker symbol for Theriva Biologics is TOVX.
-
What is the current stock price of Theriva Biologics?
As of 25-Apr-2025 the stock price of Theriva Biologics is $1.42.
-
What is the current market cap of Theriva Biologics?
The current market capitalization of Theriva Biologics is $3.93M.
-
Who are Theriva Biologics’s competitors?
Synlogic, CytomX Therapeutics, Seres Therapeutics, 4D pharma, and XBiotech are some of the 46 competitors of Theriva Biologics.
-
What is Theriva Biologics’s annual earnings per share (EPS)?
Theriva Biologics’s EPS for 12 months was -$19.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
